Navigation Links
Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
Date:5/8/2013

ponse was shown to correlate with good clinical outcomes, including improved overall survival.

The improved RNA amplification process is being used in Argos Therapeutics' ADAPT Phase 3 clinical study for AGS-003, the company's most advanced product candidate. To create AGS-003, RNA is isolated from a small tumor sample obtained from standard tumor removal surgery (nephrectomy), and dendritic cells are taken during a single leukapheresis procedure. The tumor RNA is used to "program" the dendritic cells with the entire disease-antigen repertoire to trigger an immune response against the patient's specific cancer. These antigen-loaded dendritic cells are formulated into a ready-to-use, intradermal injection.

For more information about AGS-003 and the ADAPT study, visit www.ADAPTkidneycancer.com.

About the Arcelis™ Technology Platform

Arcelis is a fully personalized, active immunotherapy technology that captures all antigens, including mutated and variant antigens that are specific to each patient's disease. It has been shown to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that are associated with toxicity. The technology can be leveraged to manufacture personalized therapies for any cancer or infectious disease.

The Arcelis process integrates readily into many current treatment paradigms, using only a small tumor or blood sample and the patient's own dendritic cells, which are derived and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient sample to program the dendritic cells to target the entire disease-antigen repertoire. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered as an intradermal injection to produce the desired patient-specific immune response.

Arcelis technology also overcomes many of the manufact
'/>"/>

SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Collegium Announces Results of Chronic Pain Patient Survey - Confirms Significant Unmet Medical Need for a Differentiated, Abuse-Deterrent, Extended-Release Opioid
4. New CDC Study Confirms Effectiveness of UV-C Disinfection in Reducing Harmful Pathogens for Hospitals
5. Lilly Confirms Date and Conference Call for First-Quarter 2013 Financial Results Announcement
6. Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
7. Perrigo Confirms FDA Approval For Testosterone Gel 1%
8. New Analysis Confirms Albumin Preserves Kidney Function and Improves Survival in Common Abdominal Infection of Liver Disease
9. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
10. Quest Diagnostics Confirms Investor Day on November 16
11. TUV Rheinland Confirms Apparent Fraud in Mislabeling of DRX Products Manufactured by HTRD and Excite Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... its common stock consisting of 1,475,506 shares to be ... by certain of its stockholders. In addition, Nevro expects ... up to an additional 590,202 shares of common stock ...
(Date:6/1/2015)... , June 1, 2015 NEOVIA ONCOLOGY ... engaged in the development and commercialization of novel, ... it has met with the U.S. Food and ... filing of an Investigational New Drug (IND) application ... a result of the meeting, Neovia has clarified ...
(Date:6/1/2015)... Novel t reatments   entering the squamous ... GBI Research . The ... primarily by the introduction of numerous premium therapies, particularly in ... combine with generic chemotherapies. Analysis from business intelligence ... to 2020 - forecasts the value of the NSCLC ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3Neovia Oncology Announces First IND Meeting 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3
... Pharmasset, Inc.,(Nasdaq: VRUS ), a clinical stage pharmaceutical ... viral,infections, reported financial results for the fiscal year ended September ... cash and cash,equivalents and short term investments. , ... Clevudine , ...
... PHILADELPHIA, December 11, Rosetta Genomics, Ltd. (NASDQ: ROSG), ... the,commercial availability of its first diagnostic test, miRview(TM) ... Genomics,CLIA-certified lab in Philadelphia. , ... may contact 1-888-522-7971, or visit the,company,s website ...
Cached Medicine Technology:Pharmasset Reports Fiscal Year End 2008 Financial Results 2Pharmasset Reports Fiscal Year End 2008 Financial Results 3Pharmasset Reports Fiscal Year End 2008 Financial Results 4Pharmasset Reports Fiscal Year End 2008 Financial Results 5Pharmasset Reports Fiscal Year End 2008 Financial Results 6Pharmasset Reports Fiscal Year End 2008 Financial Results 7Pharmasset Reports Fiscal Year End 2008 Financial Results 8Pharmasset Reports Fiscal Year End 2008 Financial Results 9Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 2Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 3Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 4Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 5
(Date:6/1/2015)... June 01, 2015 KC and Monica ... $88,000 of the best superfood products in ... floods in Texas. , "Monica and I are ... News in distributing Living Fuel Super Meals - SuperBerry®, ... millennial floods in Texas," KC Craichy said. "We have ...
(Date:6/1/2015)... Atlanta, GA (PRWEB) June 01, 2015 ... leading publisher of clinical journals in the areas of ... pleased to announce that it has expanded upon its ... newest journal, Hospital Medicine Practice, in a mobile ... smartphones and tablets. , “We are very excited ...
(Date:6/1/2015)... The session, entitled “Building the Blueprint for Tomorrow’s Vehicle ... Automotive Americas, senior representatives from Ford and Delphi, ... by Andy Gryc of CX3 Marketing. The discussion will ... software in connected vehicles and autonomous cars, and will ... ecosystem can fit into new vehicle software. , ...
(Date:6/1/2015)... Strategic Radiology (SR) announced today that Rome Radiology Group ... SR coalition of progressive, independent radiology groups geographically dispersed ... have access to collective resources in all aspects of ... of subspecialized radiology services. With the addition of RRG, ... based radiology group practices. , “We are all ...
(Date:6/1/2015)... PA (PRWEB) June 01, 2015 It ... and sanitary in order to protect both care providers ... that there needs to be a way to put ... Line is a line of home-healthcare products that promotes ... care providers and patients safe from germs and disease. ...
Breaking Medicine News(10 mins):Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 2Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 3Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 2Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 3Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 2Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 3Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 4
... came into being in the seventies, evolved into an essential component ... increase with mounting pressure on pharma and biotech companies to lower ... projected to exceed $26.2 billion by the year 2012. , ... ...
... that allows more efficient use of larger cleanrooms. , ... ... designer, fabricator and installer of cleanrooms and cleanroom equipment ... into the AireCell line of extrusions. The new extrusion allows ...
... SuperFood with Super Antioxidant provides ... environmental stress, ORLANDO, Fla., Oct. 21 ... (Chennai, India) are jointly introducing a,new organic ... complex,of organic spirulina and astaxanthin in a ...
... 21, 2008) Gastroesophageal reflux disease (GERD) is ... in GI and primary care clinics, however physicians ... trials of medications and their own observations and ... Gastroenterological Association (AGA) Institute has published evidence-based guidelines ...
... of $25 Tickets Available for Purchase at the Pine Avenue ... Entrance to the Long Beach Convention Center, LOS ANGELES, ... The Village event tonight from 5:00 p.m. to 9:00 p.m.,at the ... Night at The Village will,transform the Long Beach Convention Center,s exhibit ...
... Promotes Positive Options, Educates about Dangers of Alcohol, ... 24 school districts have been named by the ... 2008 Alcohol Awareness Poster,Contest., The awards recognize ... message that underage drinking is dangerous. The,PLCB,s annual ...
Cached Medicine News:Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 2Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 3Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 4Health News:Gerbig Engineering Introduces 7 " Deep Extrusions for Cleanroom Construction 2Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 2Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 3Health News:AGA releases evidence-based GERD guidelines 2Health News:AGA releases evidence-based GERD guidelines 3Health News:Maria Shriver to Debut 'Night at The Village' Event with Rachael Ray, Billie Jean King, Dr. Mehmet Oz and Rocco DiSpirito 2Health News:Maria Shriver to Debut 'Night at The Village' Event with Rachael Ray, Billie Jean King, Dr. Mehmet Oz and Rocco DiSpirito 3Health News:PLCB Honors Winners of 2008 Alcohol Awareness Poster Contest 2Health News:PLCB Honors Winners of 2008 Alcohol Awareness Poster Contest 3Health News:PLCB Honors Winners of 2008 Alcohol Awareness Poster Contest 4
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.2 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 3.0 mm angled double bevel. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 2.85 mm slit. Blade tip dimension: 14.1 mm x 2.85 mm x 3.3 mm....
Full Handle Laseredge Slit Blade Knife, 2.8 mm angled double bevel. Blade tip dimension: N/A x 2.8 mm x N/A....
Medicine Products: